课题基金 / 基金详情

NTBC THERAPY OF TYROSINEMIA TYPE I

NTBC THERAPY OF TYROSINEMIA TYPE I
I 型酪氨酸血症的 NTBC 治疗
批准号：
6244584
负责人：
JESS G THOENE
金额：
$2.22万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-20 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244584
关键词：
alpha fetoprotein aminoacid metabolism clinical research clinical trials drug screening /evaluation enzyme inhibitors human subject human therapy evaluation metabolism disorder chemotherapy oxygenases thiocyanates tyrosinemias

项目摘要

项目成果

JESS G THOENE的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Tyrosinemia Type I is a lethal inherited inborn error of metabolism which produces cirrhosis of the liver and hepatocellular carcinoma. Until recently, the only effective therapy was liver transplant. The drug NTBC has been developed as an inhibitor of 4-hydroxyphenylpyruvate dioxygenase. The drug is well tolerated and produces dramatic biochemical improvement. Long-term studies of the drug to determine if it avoids cirrhosis and hepatocellular carcinoma are in process and the drug has been adopted by a pharmaceutical company. One patient is being studied at the University of Michigan.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TK019: A Study of Replagal Enzyme Replacement Therapy
  • 批准号：
    7044000
  • 项目类别：
  • 资助金额：
    $0.3万
  • 财政年份：
    2003
  • 负责人：
    JESS G THOENE
  • 依托单位：
    TULANE UNIVERSITY OF LOUISIANA
NTBC THERAPY OF TYROSINEMIA TYPE I
AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS
NTBC THERAPY OF TYROSINEMIA TYPE I